{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:33:38Z","timestamp":1777948418743,"version":"3.51.4"},"reference-count":85,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Atypical chronic myeloid leukemia (aCML) is a rare form of myelodysplastic (MDS)\/myeloproliferative neoplasm (MPN) overlap disorder characterized by neutrophilic leukocytosis with circulating immature myeloid cells (IMC), frequent hepatosplenomegaly, and poor prognosis with high rates of leukemic transformation. In the 2022 World Health Organization (WHO) classification, aCML was therefore renamed to \u201cMDS\/MPN with neutrophilia.\u201d Diagnostic criteria for aCML include leukocytosis\u2009\u2265\u200913\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L, circulating IMC\u2009\u2265\u200910%, dysgranulopoiesis, and at least one cytopenia for MDS\u2010thresholds (per International Consensus Classification [ICC]). Bone marrow is hypercellular due to granulocytic proliferation, associated with dysplasia in granulocytes \u00b1 other cell lines. Mutations can be used to support the diagnosis in both classifications, that is,\n                    <jats:italic>SETBP1<\/jats:italic>\n                    and\n                    <jats:italic>ASXL1<\/jats:italic>\n                    or\n                    <jats:italic>SETBP1<\/jats:italic>\n                    and\/or\n                    <jats:italic>ETNK1<\/jats:italic>\n                    . Absence of monocytosis, basophilia, or eosinophilia, &lt;20% blasts, and exclusion of other MPN, MDS\/MPN, and tyrosine kinase fusions are mandatory. Cytogenetic abnormalities are identified in roughly 20%\u201340% of aCML patients, along with a complex genomic context with high rates of recurrent somatic mutations in\n                    <jats:italic>ASXL1<\/jats:italic>\n                    ,\n                    <jats:italic>SETBP1<\/jats:italic>\n                    ,\n                    <jats:italic>SRSF2<\/jats:italic>\n                    ,\n                    <jats:italic>TET2<\/jats:italic>\n                    ,\n                    <jats:italic>EZH2<\/jats:italic>\n                    , and, less frequently, in\n                    <jats:italic>NRAS\/KRAS<\/jats:italic>\n                    ,\n                    <jats:italic>CBL<\/jats:italic>\n                    ,\n                    <jats:italic>CSF3R<\/jats:italic>\n                    ,\n                    <jats:italic>JAK2<\/jats:italic>\n                    , and\n                    <jats:italic>ETNK1<\/jats:italic>\n                    . Unfortunately, effective risk stratification systems for identifying prognostic subgroups of aCML patients are lacking, resulting in the absence of a standard of care for its management. The most used agents include hydroxyurea, interferon, hypomethylating agents, and JAK inhibitors, although none of them are disease\u2010modifying. Allogeneic hematopoietic stem cell transplant remains the only potentially curative approach and should be considered in all eligible patients. Actionable mutations (\n                    <jats:italic>CSF3R<\/jats:italic>\n                    ,\n                    <jats:italic>NRAS\/KRAS<\/jats:italic>\n                    , and\n                    <jats:italic>KIT<\/jats:italic>\n                    ) have also been identified, supporting the development of new agents targeting the involved pathways.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70270","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:41:47Z","timestamp":1765284107000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"first","affiliation":[{"name":"Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy"},{"name":"Department of Oncology and Hemato\u2010Oncology University of Milan Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Gianelli","sequence":"additional","affiliation":[{"name":"Division of Pathology, ASST Santi Paolo e Carlo San Paolo Hospital Milan Italy"},{"name":"Department of Health Sciences University of Milan Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy"},{"name":"Department of Oncology and Hemato\u2010Oncology University of Milan Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27321"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_2_11_5_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours and Lymphoid Tissue","author":"Swerdlow SH","year":"2001"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000497"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.03.015"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.07.013"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011181"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33622"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008204"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008393002748"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05106-8"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-553800"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004229"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.101133"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1946"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24722"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000611"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2232495"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.756348"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.06.032"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2495"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.113159"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.133"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04462-8"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.294"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9128-9"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227363"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205690"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.337"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.06.001"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-325241"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011205"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399774"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-579466"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19721-w"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932608"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214514"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2024.152317"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.002417"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107345"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34616"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013255"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1677461"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101014"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143474"},{"key":"e_1_2_11_49_1","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia M","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010722"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06032-z"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10832"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000448"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-693630"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2915"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23018"},{"key":"e_1_2_11_57_1","first-page":"114","article-title":"The first case of decitabine successfully in treatment of atypical chronic myeloid leukemia with CEBPA double mutation","volume":"2","author":"Mao L","year":"2013","journal-title":"Chemotherapy"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.986477"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215605662"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3977"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00895"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24972"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210743"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4265-19"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1327834"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1353818"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-19-1806"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.2.445.445"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-509976"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2014.07.002"},{"key":"e_1_2_11_71_1","article-title":"Durable disease control with MEK inhibition in a patient with NRAS\u2010mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna V","year":"2015","journal-title":"Cureus"},{"key":"e_1_2_11_72_1","article-title":"Trametinib: could it be a promising drug to treat atypical chronic myeloid leukemia?","volume":"14","author":"Elsayed M","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2023.100371"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10073-w"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181673"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2586"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07884"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01125-4"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01476-8"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1274"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028000"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704686"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2011.01351.x"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14619"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27641"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70270","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70270","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:59:50Z","timestamp":1777795190000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":85,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/hem3.70270"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70270","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70270"}}